Breast cancer is the most common malignancy in women in Poland and the entire world, but thanks to early diagnostics and efficacious therapeutic methods, its prognosis is good. in some patients with advanced breast cancer, long-term survival is observed, which is why it is essential to select the most appropriate therapy, and to follow up on the course of disease and possible adverse events related to the treatment applied. The slow development of hormone-receptor-positive cancer, and a multitude of therapeutic options constitute a real challenge in palliative treatment. The use of fulvestrant resulted in a good response in both of the presented cases, and did not in any way comprise the daily lives of the patients over a long period of time.
has given way to mortality related to lung cancer, which is directly linked to an increase in the popularity of tobacco smoking amongst women [1] . Early detection of breast cancer, followed by appropriate treatment, makes it possible to cure most patients now. Some women are diagnosed with advanced disease, though, or experience cancer recurrence despite previous radical therapy. However, even in those patients, it is sometimes possible to achieve long-term survival. Thus, it is essential to plan the treatment of that slowly progressing disease carefully, closely monitoring the course of disease as well the possible adverse events related to the therapy administered and to patient comorbidities. Tamoxifen plays an essential part in the treatment of both preand post-menopausal female patients. its action blocks the oestrogen receptor in breast tissues, inhibiting cancer recurrence, and lowering the risk of cancer development in the contralateral breast. At the same time, the drug stimulates the oestrogen receptor in endometrium, thus increasing the risk of neoplasia in the uterine cavity. on the other hand, it also stimulates bone formation and the cardiovascular system. due to the different effects on the oestrogen receptor in different locations, inhibitory or excitatory, tamoxifen belongs to a group of medicines known as selective oestrogen receptor modulators [2] . A drug that only has an inhibitory effect is fulvestrant, which competitively inhibits the binding of oestradiol with the oestrogen receptor, leading to its degradation. Progression of cancer despite the use of fulvestrant may testify to the presence of resistance mechanisms, and to the development of independent hormone stimulation pathways [3] .
Aromatase inhibitors are mainly used in post-menopausal patients. Their role consists in inhibiting aromatization of androgens into oestrogens in the adipose tissue, which constitutes the primary source of sex hormones in post-menopausal women.
When selecting hormone therapies, the sequence of therapeutics depends on the advancement of tumour, the patient's general condition and concomitant diseases. Even in metastatic disease, without severe symptoms, hormone treatment is possible, with chemotherapy reserved primarily for organ crises or rapid disease progression [4] .
The below descriptions of the course of disease in two of our patients testify to a high and long-lasting efficacy of the hormone therapies involved. 
ConCluSIonS
Breast cancer has become a chronic disease, and the two cases discussed above reflect the phenomenon very well. Fulvestrant is a drug that is active both following an earlier anti-oestrogen therapy as well as in the first line of dissemination, as confirmed by the Falcon study results. in the group of patients receiving fulvestrant, time to progression was 16.6 months, and was 2.8 months longer as compared with the anastrozole study arm (13.8 months) [5] .
Treating breast cancer patients, we administer hormone therapy in bone and lymph node metastases, and ever more willingly also in organ metastases, with the presented two cases being a good example of the current trend.
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